← The Wire
GLSINasdaq
Greenwich LifeSciences, Inc.
Pharmaceutical Preparations · DE · CIK 1799788
Greenwich LifeSciences develops GLSI-100, an immunotherapy to prevent breast cancer recurrences by targeting HER2/neu positive patients
$353M
Market cap
$23.25
Last close
+17.4%
1D
-2.1%
5D
208K
Volume
Price · last 39 sessions+5.8%
May 4L $18.33 · H $29.23Jun 29
78
Total filings
Jun 4, 2026
Last filing
12/31
Fiscal year end
10-Q10-QJun 4, 202610-K10-KJun 1, 20268-KShareholder VoteDec 18, 202510-Q10-QNov 14, 2025DEFA14ADEFA14ANov 3, 2025DEF 14ADEF 14ANov 3, 202510-Q10-QAug 14, 20258-KAuditor ChangeJul 24, 202510-Q10-QMay 20, 202510-K10-KApr 15, 20258-KShareholder VoteDec 19, 202410-Q10-QNov 14, 2024DEFA14ADEFA14ANov 1, 2024DEF 14ADEF 14ANov 1, 202410-Q10-QAug 14, 20248-KMaterial Agreement · Equity IssuanceJun 17, 202410-Q10-QMay 20, 202410-K10-KApr 15, 20248-KAuditor ChangeFeb 20, 20248-KCompany UpdateFeb 14, 20248-KShareholder VoteDec 15, 2023DEFA14ADEFA14AOct 25, 2023DEF 14ADEF 14AOct 25, 202310-Q10-QOct 19, 202310-Q10-QAug 21, 202310-Q10-QMay 22, 20238-KCompany UpdateApr 13, 202310-K10-KMar 31, 20238-KCompany UpdateMar 13, 20238-KShareholder VoteDec 9, 202210-Q10-QNov 14, 2022DEFA14ADEFA14AOct 19, 2022DEF 14ADEF 14AOct 19, 202210-Q10-QAug 15, 20228-KMaterial AgreementJul 12, 2022424B5424B5Jul 12, 20228-KCompany UpdateJul 12, 20228-KCompany UpdateJul 11, 202210-K/A10-K/AJun 24, 2022SC 13GSC 13GJun 22, 202210-Q10-QMay 20, 202210-K10-KMar 21, 20228-KShareholder VoteDec 15, 20218-KCompany UpdateDec 13, 202110-Q10-QNov 15, 20218-KReg FD DisclosureNov 10, 2021DEFA14ADEFA14AOct 20, 2021DEF 14ADEF 14AOct 19, 202110-Q10-QAug 13, 20218-KCompany UpdateJun 10, 20218-KCompany UpdateJun 9, 202110-Q10-QMay 20, 20218-KCompany UpdateApr 20, 20218-KCompany UpdateApr 15, 20218-KCompany UpdateApr 13, 202110-K10-KMar 31, 20218-KMaterial Agreement · Company UpdateDec 22, 2020424B4424B4Dec 18, 2020S-1S-1Dec 15, 20208-KCompany UpdateDec 15, 20208-KCompany UpdateDec 14, 20208-KCompany UpdateDec 10, 2020SC 13DSC 13DNov 30, 20208-KCompany UpdateNov 24, 20208-KReg FD Disclosure · Company UpdateNov 19, 202010-Q10-QNov 16, 20208-KCompany UpdateNov 13, 2020SC 13DSC 13DOct 13, 20208-KReg FD Disclosure · Company UpdateOct 9, 20208-KExecutive Change · Bylaw AmendmentOct 1, 2020424B4424B4Sep 28, 2020424B4424B4Sep 28, 20208-KMaterial Agreement · Company UpdateSep 28, 2020S-1/AAMENDMENT NO. 4 TO FORM S-1Sep 10, 2020S-1/AAMENDMENT NO. 3 TO FORM S-1Sep 9, 2020S-1/AAMENDMENT NO. 2 REGISTRATION STATEMENTJun 26, 2020S-1/AREGISTRATION STATEMENTJun 23, 2020S-1REGISTRATION STATEMENT ON FORM S-1May 29, 2020
Insider Activity
In the 90 days to Jan 13, 2026: 1 insider bought $489K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 13, 2026 | Patel SnehalCEO and CFO | Buy | 1,800 | $29.83 | $54K |
| Jan 12, 2026 | Patel SnehalCEO and CFO | Buy | 2,900 | $27.54 | $80K |
| Dec 31, 2025 | Patel SnehalCEO and CFO | Buy | 4,300 | $21.36 | $92K |
| Dec 30, 2025 | Patel SnehalCEO and CFO | Buy | 2,900 | $21.73 | $63K |
| Dec 18, 2025 | Patel SnehalCEO and CFO | Buy | 4,100 | $12.62 | $52K |
| Nov 25, 2025 | Patel SnehalCEO and CFO | Buy | 4,600 | $8.37 | $39K |
| Nov 7, 2025 | Patel SnehalCEO and CFO | Buy | 10,600 | $8.43 | $89K |
| Oct 31, 2025 | Patel SnehalCEO and CFO | Buy | 2,300 | $9.26 | $21K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance